{"certainAgreement":{"otherDetails":"Institution's individual results may be submitted for publication only after the results of the multicenter study are published, 18 months after study completion at all sites, or notification from Stemline Therapeutics, Inc. that submission of a multicenter publication is no longer planned, whichever shall occur first.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"This study was terminated early due to slow accrual and changes to Sponsor's development program priorities. The third dose level (12 µg/kg/day), for Phase 2, was not investigated."},"pointOfContact":{"email":"clinicaltrials@menarinistemline.com","organization":"Stemline Therapeutics, Inc.","phone":"877-332-7967","title":"Ira Gupta, MD, Senior Vice President, Clinical Development & Medical Affairs - Hematology"}}